DB:AP8

Stock Analysis Report

Executive Summary

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States.


Snowflake Analysis

Limited growth and overvalued.


Similar Companies

Share Price & News

How has Aptevo Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AP8's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.4%

AP8

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-68.6%

AP8

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: AP8 underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: AP8 underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

AP8IndustryMarket
7 Day2.4%-2.3%-0.2%
30 Day-27.1%-3.2%0.3%
90 Day-19.3%6.3%3.7%
1 Year-68.6%-68.6%8.6%8.4%17.2%13.7%
3 Year-74.5%-74.5%44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Aptevo Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aptevo Therapeutics undervalued compared to its fair value and its price relative to the market?

1.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AP8's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AP8's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AP8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AP8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AP8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AP8 is good value based on its PB Ratio (1.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Aptevo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

17.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AP8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AP8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AP8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AP8's revenue (23.6% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: AP8's revenue (23.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AP8's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aptevo Therapeutics performed over the past 5 years?

12.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AP8 is currently unprofitable.

Growing Profit Margin: AP8 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AP8 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.1% per year.

Accelerating Growth: Unable to compare AP8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AP8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: AP8 has a negative Return on Equity (-251.47%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Aptevo Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AP8's short term assets ($36.8M) do not cover its short term liabilities ($37.3M).

Long Term Liabilities: AP8's short term assets ($36.8M) exceed its long term liabilities ($3.6M).


Debt to Equity History and Analysis

Debt Level: AP8's debt to equity ratio (99.8%) is considered high.

Reducing Debt: Insufficient data to determine if AP8's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: AP8 has a high level of physical assets or inventory.

Debt Coverage by Assets: AP8's debt is covered by short term assets (assets are 1.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AP8 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AP8 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -0.3% each year


Next Steps

Dividend

What is Aptevo Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AP8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AP8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AP8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AP8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AP8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Marvin White (57yo)

3.5yrs

Tenure

US$1,104,819

Compensation

Mr. Marvin L. White has been the Chief Executive Officer and President at Aptevo Therapeutics Inc. since August 1, 2016. Mr. White has been the President and Chief Executive Officer at The MLW Advisory Gro ...


CEO Compensation Analysis

Compensation vs Market: Marvin's total compensation ($USD1.10M) is above average for companies of similar size in the German market ($USD412.50K).

Compensation vs Earnings: Marvin's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Marvin White
President3.5yrsUS$1.10m0.65% $133.4k
Jeffrey Lamothe
Senior VP3.6yrsUS$691.99k0.17% $34.1k
Scott Stromatt
Consultant3.6yrsUS$708.88k0.52% $106.5k
Randy Maddux
Senior VP of Operations & Chief Manufacturing Officer3.6yrsno data0.17% $34.1k
Jane Gross
Senior VP & Chief Scientific Officer3.4yrsno data0.24% $49.8k
Stacey Jurchison
Senior Director of Investor Relations & Corporate Communications0yrsno datano data
Shawnte Mitchell
Senior VP of Corporate Affairs3.6yrsno data0.18% $36.6k
Michael Adelman
Senior VP of Commercial Operations2.1yrsno data0.16% $32.0k

3.6yrs

Average Tenure

57yo

Average Age

Experienced Management: AP8's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marvin White
President3.5yrsUS$1.10m0.65% $133.4k
Daniel Abdun-Nabi
Director3.5yrsUS$132.50k0.32% $65.8k
Fuad El-Hibri
Chairman3.5yrsUS$138.72k2.48% $510.9k
Zsolt Harsanyi
Independent Director3.5yrsUS$157.29k0.19% $38.8k
John Niederhuber
Lead Independent Director3.5yrsUS$169.70k0.10% $21.2k
Barbara Kunz
Independent Director3.5yrsUS$162.09k0.10% $20.6k
Grady Grant
Independent Director3.5yrsUS$152.44k0.10% $20.6k

3.5yrs

Average Tenure

63yo

Average Age

Experienced Board: AP8's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.7%.


Top Shareholders

Company Information

Aptevo Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptevo Therapeutics Inc.
  • Ticker: AP8
  • Exchange: DB
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$22.200m
  • Listing Market Cap: US$20.571m
  • Shares outstanding: 45.28m
  • Website: https://aptevotherapeutics.com

Number of Employees


Location

  • Aptevo Therapeutics Inc.
  • 2401 4th Avenue
  • Suite 1050
  • Seattle
  • Washington
  • 98121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APVONasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDAug 2016
AP8DB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2016
0HH3LSE (London Stock Exchange)YesCommon SharesGBUSDAug 2016

Biography

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:05
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.